Reversal of Ketamine-Induced Working Memory Impairments by the GABAAα2/3 Agonist TPA023

Biological Psychiatry

Volumn 67, Issue 10, 2010, Pages 998-1001

  Castner, Stacy A ^a,b   Arriza, Jeffrey L ^c   Roberts, John C ^c   Mrzljak, Ladislav ^c   Christian, Edward P ^c   Williams, Graham V ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Cognition; disinhibition; NMDA; nonhuman primate; prefrontal cortex; schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 7 (1,1 DIMETHYL) 6 2 ETHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 3 (2 FLUOROPHENYL) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; GABA A ALPHA2 AGONIST; GABA A ALPHA3 AGONIST; KETAMINE; TPA 023; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; COGNITION; CONTROLLED STUDY; DRUG INHIBITION; HALLUCINATION; MEMORY DISORDER; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; WORKING MEMORY;

ANIMALS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; KETAMINE; MACACA MULATTA; MEMORY DISORDERS; MEMORY, SHORT-TERM; PYRIDAZINES; RECEPTORS, GABA-A; TRIAZOLES;

EID: 77951620095     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2010.01.001     Document Type: Article

References (20)

1. Green M.F., Kern R.S., Braff D.L., and Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff?". Schizophr Bull 26 (2000) 119-136
2. Guidotti A., Auta J., Davis J.M., Di-Giorgi-Gerevini V., Dwivedi Y., Grayson D.R., et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: A postmortem brain study. Arch Gen Psychiatry 57 (2000) 1061-1069
3. Lewis D.A., Cruz D.A., Melchitzky D.S., and Pierri J.N. Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: Evidence for fewer projections from the thalamus. Am J Psychiatry 158 (2001) 1411-1422
4. Rao S.G., Williams G.V., and Goldman-Rakic P.S. Destruction and creation of spatial tuning by disinhibition: GABA(A) blockade of prefrontal cortical neurons engaged by working memory. J Neurosci 20 (2000) 485-494
5. Cobb S.R., Buhl E.H., Halasy K., Paulsen O., and Somogyi P. Synchronization of neuronal activity in hippocampus by individual GABAergic interneurons. Nature 378 (1995) 75-78
6. Howard M.W., Rizzuto D.S., Caplan J.B., Madsen J.R., Lisman J., Aschenbrenner-Scheibe R., et al. Gamma oscillations correlate with working memory load in humans. Cereb Cortex 13 (2003) 1369-1374
7. Spencer K.M., Nestor P.G., Niznikiewicz M.A., Salisbury D.F., Shenton M.E., and McCarley R.W. Abnormal neural synchrony in schizophrenia. J Neurosci 23 (2003) 7407-7411
8. Menzies L., Ooi C., Kamath S., Suckling J., McKenna P., Fletcher P., et al. Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. Arch Gen Psychiatry 64 (2007) 156-167
9. Seamans J.K., Nogueira L., and Lavin A. Synaptic basis of persistent activity in prefrontal cortex in vivo and in organotypic cultures. Cereb Cortex 13 (2003) 1242-1250
10. Wang X.J. Synaptic basis of cortical persistent activity: The importance of NMDA receptors to working memory. J Neurosci 19 (1999) 9587-9603
11. Jones R.S., and Buhl E.H. Basket-like interneurones in layer II of the entorhinal cortex exhibit a powerful NMDA-mediated synaptic excitation. Neurosci Lett 149 (1993) 35-39
12. Vutskits L., Gascon E., Potter G., Tassonyi E., and Kiss J.Z. Low concentrations of ketamine initiate dendritic atrophy of differentiated GABAergic neurons in culture. Toxicology 234 (2007) 216-226
13. Lewis D.A., Cho R.Y., Carter C.S., Eklund K., Forster S., Kelly M.A., et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry 165 (2008) 1585-1593
14. Atack J., Wong D., Fryer T., Ryan C., Sanabria S., Zhou Y., et al. Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates and man. J Pharmacol Exp Ther 332 (2010) 17-25
15. Castner S.A., and Goldman-Rakic P.S. Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology 20 (1999) 10-28
16. 2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J Psychopharmacol 21 (2007) 374-383
17. Lahti A.C., Weiler M.A., Tamara Michaelidis B.A., Parwani A., and Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25 (2001) 455-467
18. Krystal J.H., Bennett A., Abi-Saab D., Belger A., Karper L.P., D'Souza D.C., et al. Dissociation of ketamine effects on rule acquisition and rule implementation: Possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry 47 (2000) 137-143
19. Taffe M.A., Davis S.A., Gutierrez T., and Gold L.H. Ketamine impairs multiple cognitive domains in rhesus monkeys. Drug Alcohol Depend 68 (2002) 175-187
20. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31 (2008) 234-242